The company, which makes semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes), said that its drug did not provide any additional benefit over placebo in two trials of people with early Alzheimer’s. The company is planning to release more data at a presentation at the Clinical Trials on Alzheimer’s Disease conference in early December and at the Alzheimer’s and Parkinson’s Diseases conferences in March 2026.